{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-002983","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2024-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.528552+00:00","generated_at":"2026-06-06T21:16:45.809742+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Processa expands NGC-Cap into breast cancer; FDA agrees existing data supports Phase 2 trial","bullets":["FDA agreed existing data can directly support Phase 2 breast cancer trial design.","Plan to initiate Phase 2 study in advanced/metastatic breast cancer in Q3 2024.","Breast cancer represents larger market than colorectal; potential for >250,000 patients/year.","Company identified breast cancer KOLs for scientific advisory board."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-002983","json":"https://secwatch.observer/filing/0001493152-24-002983.json","markdown":"https://secwatch.observer/filing/0001493152-24-002983.md","text":"https://secwatch.observer/filing/0001493152-24-002983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224002983/0001493152-24-002983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224002983/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T21:16:45.809742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}